Aprogen Biologics (003060) Financial Statements

― Followers

Aprogen Biologics Financial Overview

Aprogen Biologics's market cap is currently ₩25.44B. The company's EPS TTM is $; its P/E ratio is -0.27; Aprogen Biologics is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 73.23B	₩ 67.38B	₩ 87.36B	₩ 65.19B	₩ 56.48B
Gross Profit	₩ -28.42B	₩ -7.58B	₩ -12.05B	₩ 27.29B	₩ 25.44B
Operating Income	₩ -122.89B	₩ -52.82B	₩ -69.95B	₩ 12.81B	₩ 10.49B
EBITDA	₩ -103.70B	₩ -51.33B	₩ -88.32B	₩ 16.01B	₩ 11.38B
Net Income	₩ -170.33B	₩ -104.98B	₩ -118.27B	₩ 5.58B	₩ 8.10B
Balance Sheet
Cash & Short-Term Investments	₩ 51.02B	₩ 38.32B	₩ 10.05B	₩ 99.07B	₩ 124.94B
Total Assets	₩ 586.99B	₩ 590.98B	₩ 589.40B	₩ 676.10B	₩ 614.62B
Total Debt	₩ 225.32B	₩ 154.02B	₩ 181.00B	₩ 134.74B	₩ 2.48B
Net Debt	₩ 200.93B	₩ 141.71B	₩ 170.94B	₩ 111.13B	₩ -32.59B
Total Liabilities	₩ 305.95B	₩ 212.29B	₩ 220.71B	₩ 173.73B	₩ 17.44B
Stockholders' Equity	₩ 207.76B	₩ 378.49B	₩ 368.69B	₩ 421.72B	₩ 507.94B
Cash Flow
Free Cash Flow	₩ -47.86B	₩ -46.45B	₩ -62.05B	₩ 24.18B	₩ -7.67B
Operating Cash Flow	₩ -38.23B	₩ -31.00B	₩ -33.65B	₩ 25.73B	₩ -6.23B
Investing Cash Flow	₩ -85.12B	₩ -51.72B	₩ -95.21B	₩ -53.00B	₩ -23.16B
Financing Cash Flow	₩ 135.14B	₩ 84.97B	₩ 115.29B	₩ 15.78B	₩ -350.26M

Currency in KRW

Aprogen Biologics Earnings and Revenue History

Income Statement >

Aprogen Biologics Debt to Assets

Balance Sheet >

Aprogen Biologics Cash Flow

Cash Flow >

Aprogen Biologics Forecast EPS vs Actual EPS

Earnings >